Dr. Escalon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1611 Nw 12th Ave
Box 016960 M851
Miami, FL 33136Phone+1 305-585-1111- Is this information wrong?
Education & Training
- Imperial CollegeExecutive MBA, 2014
- University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 2002 - 2005
- University of Texas Medical School at Houston - Ruiz Dept of Ophthalmology & Visual ScienceMSc, Clinical Research, emphasis on Immunology, 2005
- University of Miami/Jackson Health SystemResidency, Internal Medicine, 1999 - 2002
- University of Florida College of MedicineClass of 1999
- Florida State UniversityBS, Biochemistry, 1995
Certifications & Licensure
- FL State Medical License 2001 - 2026
- AZ State Medical License 2019 - 2025
- NC State Medical License 2018 - 2022
- TX State Medical License 2002 - 2005
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
- Fellow of the Year Award MD Anderson
- Young Investigator Award American Society of Clinical Oncology
- Join now to see all
Clinical Trials
- Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma Start of enrollment: 2007 Feb 01
Publications & Presentations
PubMed
- 47 citationsEUS-guided biopsy for the diagnosis and classification of lymphomaAfonso Ribeiro, Denise Pereira, Maricer P. Escalón, Mark Goodman, Gerald E. Byrne> ;Gastrointestinal Endoscopy. 2010 Apr 1
- 28 citationsCord blood transplantation: evolving strategies to improve engraftment and immune reconstitution.Maricer P. Escalón, Krishna V. Komanduri> ;Current Opinion in Oncology. 2010 Mar 1
- 14 citationsHigh rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabi...Izidore S. Lossos, Peter J. Hosein, Daniel Morgensztern, Francine Coleman, Maricer P. Escalón, Gerald E. Byrne, Joseph D. Rosenblatt, Gail Walker> ;Leukemia & Lymphoma. 2010 Feb 12
- Join now to see all
Press Mentions
- Ensysce Biosciences Receives Investigational New Drug Allowance for Its Unique PF614-MPAR™ Opioid with Overdose ProtectionApril 29th, 2021
Hospital Affiliations
- University of North Carolina HospitalsChapel Hill, North Carolina
- UMHC-Sylvester Comprehensive Cancer CenterMiami, Florida
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: